Does Attorney Advertising Stimulate Adverse Event Reporting?

被引:0
|
作者
Tippett, Elizabeth C. [1 ]
Chen, Brian K. [2 ]
机构
[1] Univ Oregon, Sch Law, Eugene, OR 97403 USA
[2] Univ South Carolina, Arnold Sch Publ Hlth, Columbia, SC 29208 USA
关键词
POSTMARKETING SURVEILLANCE; FDA;
D O I
暂无
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Law firms and legal referral companies spend about $114 million per year(1 )on television advertisements soliciting patients for mass tort lawsuits against drug companies and medical device makers ("drug injury advertising").(2) These advertisements warn viewers about a particular adverse event associated with a drug or medical device, and advise them to call the number listed on-screen if they have experienced that adverse event.(3) This study is the first to investigate whether drug injury advertising volume is associated with increased adverse event reporting through the Federal Adverse Event Reporting System (FAERS). The study analyzed 412,901 adverse event reports to FAERS, involving twenty-eight groups of drugs targeted in drug injury advertising over a one-year period. These individual reports were then aggregated on a weekly and monthly basis and analyzed to test associations between FAERS reporting volume and attorney advertising volume, relative Google search volume, media hits, and Food and Drug Administration (FDA) safety interventions. The study revealed no significant relationship between drug injury advertising volume and the volume of adverse event reports. By contrast, FDA safety actions, Google search volume, and media hits were positively correlated with FAERS reports.
引用
收藏
页码:501 / 522
页数:22
相关论文
共 50 条
  • [1] Does Error and Adverse Event Reporting by Physicians and Nurses Differ?
    Rowin, Ethan J.
    Lucier, David
    Pauker, Stephen G.
    Kumar, Sanjaya
    Chen, Jack
    Salem, Deeb N.
    [J]. JOINT COMMISSION JOURNAL ON QUALITY AND PATIENT SAFETY, 2008, 34 (09): : 537 - 545
  • [2] Adverse event reporting
    Kruft, Bonnie
    Nelson, Lindsay A.
    Stewart, Jeanette A.
    Stewart, William C.
    [J]. OPHTHALMOLOGY, 2007, 114 (07) : 1420 - 1420
  • [3] Does adverse event reporting support an increased incidence of anaphylaxis with rocuronium?
    Bishop, MJ
    O'Donnell, JT
    Bhananker, SM
    Salemi, JR
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1212 - 1212
  • [4] Introduction of a Mobile Adverse Event Reporting System Is Associated With Participation in Adverse Event Reporting
    Rubin, Daniel S.
    Pesyna, Colin
    Jakubczyk, Sharon
    Liao, Chuanhong
    Tung, Avery
    [J]. AMERICAN JOURNAL OF MEDICAL QUALITY, 2019, 34 (01) : 30 - 35
  • [5] Serious Adverse Event Reporting
    Stewart, William C.
    Stewart, Jeanette A.
    Demos, Christina M.
    Turner, Meredith
    [J]. OPHTHALMOLOGY, 2009, 116 (12) : 2485 - 2486
  • [6] Adverse Drug Event Reporting
    Vaughan, William
    [J]. HEALTH AFFAIRS, 2012, 31 (08) : 1911 - 1911
  • [7] Adverse Event Reporting in Otolaryngology
    Pereira, Nicola M.
    Sclafani, Anthony P.
    Kacker, Ashutosh
    [J]. LARYNGOSCOPE, 2021, 131 (03): : 509 - 512
  • [8] CBER adverse event reporting
    Gilbert, CD
    Chew, NJ
    [J]. BIOPHARM-THE TECHNOLOGY & BUSINESS OF BIOPHARMACEUTICALS, 1995, 8 (07): : 14 - &
  • [9] Discontinuation of Direct Oral Anticoagulants in Response to Attorney Advertisements: Data From the FDA Adverse Event Reporting System
    Mohamoud, Mohamed
    Patanavanich, Saharat
    Crew, Page
    McCulley, Lynda
    Munoz, Monica
    Kortepeter, Cindy
    Jones, S. Christopher
    Woronow, Daniel
    Dal Pan, Gerald
    [J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (09) : 962 - 963
  • [10] Adverse events and adverse event reporting systems
    Huebler, M.
    Moellemann, A.
    Metzler, H.
    Koch, T.
    [J]. ANAESTHESIST, 2007, 56 (10): : 1067 - +